Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Vinflunine: a new microtubule inhibitor agent Bennouna J; Delord JP; Campone M; Nguyen LClin Cancer Res 2008[Mar]; 14 (6): 1625-32Vinflunine (Javlor) is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. Vinflunine is obtained by semisynthesis using superacidic chemistry to selectively introduce two fluorine atoms at the 20' position of the catharanthine moiety. This compound has been selected for clinical development on the basis of encouraging preclinical activity that warrants study in patients with a wide spectrum of solid tumors. Clinically significant activity has been seen in phase II studies, mainly in the treatment of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast. Vinflunine is currently in phase III trial assessment in patients with (second line) transitional cell carcinoma of the urothelium and first-line advanced breast cancer. The efficacy of vinflunine in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen was confirmed by a large phase III trial.|Animals[MESH]|Breast Neoplasms/drug therapy[MESH]|Carcinoma, Transitional Cell/drug therapy/pathology[MESH]|Carcinoma/drug therapy[MESH]|Clinical Trials as Topic[MESH]|Drug Evaluation, Preclinical[MESH]|Humans[MESH]|Lung Neoplasms/drug therapy[MESH]|Models, Biological[MESH]|Neoplasms/*drug therapy/metabolism[MESH]|Treatment Outcome[MESH]|Tubulin Modulators/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Urologic Neoplasms/drug therapy/pathology[MESH]|Urothelium/pathology[MESH]|Vinblastine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use[MESH] |
